Lin Lili, Zhang Wenda, Chen Yongjian, Ren Wei, Zhao Jianli, Ouyang Wenhao, He Zifan, Su Weifeng, Yao Herui, Yu Yunfang
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Breast Tumor Centre, Phase I Clinical Trial Centre, Medical Research Center, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Heliyon. 2023 Mar 12;9(3):e14450. doi: 10.1016/j.heliyon.2023.e14450. eCollection 2023 Mar.
Although immunotherapy has revolutionized cancer management, most patients do not derive benefits from it. Aiming to explore an appropriate strategy for immunotherapy efficacy prediction, we collected 6251 patients' transcriptome data from multicohort population and analyzed the data using a machine learning algorithm. In this study, we found that patients from three immune gene clusters had different overall survival when treated with immunotherapy ( 0.001), and that these clusters had differential states of hypoxia scores and metabolism functions. The immune gene score showed good immunotherapy efficacy prediction (AUC was 0.737 at 20 months), which was well validated. The immune gene score, tumor mutation burden, and long non-coding RNA score were further combined to build a tumor immune microenvironment signature, which correlated more strongly with overall survival (AUC, 0.814 at 20 months) than when using a single variable. Thus, we recommend using the characterization of the tumor immune microenvironment associated with immunotherapy efficacy a multi-omics analysis of cancer.
尽管免疫疗法彻底改变了癌症治疗方式,但大多数患者并未从中获益。为了探索一种预测免疫疗法疗效的合适策略,我们从多队列人群中收集了6251例患者的转录组数据,并使用机器学习算法对数据进行了分析。在本研究中,我们发现来自三个免疫基因簇的患者在接受免疫疗法治疗时总生存期不同(P = 0.001),并且这些簇具有不同的缺氧评分状态和代谢功能。免疫基因评分显示出良好的免疫疗法疗效预测能力(20个月时AUC为0.737),且得到了充分验证。进一步将免疫基因评分、肿瘤突变负荷和长链非编码RNA评分相结合,构建了一个肿瘤免疫微环境特征,与使用单一变量相比,该特征与总生存期的相关性更强(20个月时AUC为0.814)。因此,我们建议利用与免疫疗法疗效相关的肿瘤免疫微环境特征——对癌症进行多组学分析。